Omeros Form 4: Demopulos receives annual 15k option grant
Rhea-AI Filing Summary
Omeros Corporation (OMER) – Form 4 filing dated 07/01/2025
Non-employee director Dr. Peter A. Demopulos was automatically granted a stock option for 15,000 common shares under the company’s director compensation policy following the annual shareholder meeting on 06/27/2025. The option’s key terms are:
- Exercise price: $3.20 per share
- Expiration: 06/27/2035 (10-year tenor)
- Vesting: fully vests the day before the 2026 annual meeting, contingent on continued board service
- Ownership designation: direct (D); post-grant derivative holdings reported at 15,000 options
The filing reflects routine annual equity compensation for board members and does not disclose any open-market purchases or sales of common shares.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director option grant; aligns incentives but immaterial to valuation.
The automatic issuance of 15,000 options at $3.20 to Dr. Demopulos is standard practice under Omeros’ director pay program. At today’s share price, the notional value is modest and does not alter control dynamics or ownership concentration. Such equity grants are intended to maintain director–shareholder alignment and are viewed positively from a governance perspective, yet the scale is far too small to influence financial metrics or liquidity. No buying or selling of common stock occurred, so market impact should be negligible.
TL;DR: Neutral event; no immediate trading signal.
A 15k-unit option grant with a 10-year life is commonplace and represents less than 0.03 % of shares outstanding. Because it vests in 12 months, it does not pose near-term dilution risk. I view the disclosure as housekeeping—useful for tracking insider incentives but not for portfolio action. Impact on earnings, cash flow, and strategic outlook is nil; therefore, I assign a neutral rating.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
Footnotes (1)
- Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.
